PETER HIATT to Male
This is a "connection" page, showing publications PETER HIATT has written about Male.
Connection Strength
0.075
-
Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics. 1999 Mar; 103(3):619-26.
Score: 0.007
-
Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics. 1998 Jun; 101(6):1013-9.
Score: 0.006
-
Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J. 1998 Mar; 17(3):217-24.
Score: 0.006
-
High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr. 1994 Oct; 125(4):635-41.
Score: 0.005
-
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014 Dec; 13(6):674-80.
Score: 0.005
-
Association of lung function, chest radiographs and clinical features in infants with cystic fibrosis. Eur Respir J. 2013 Dec; 42(6):1545-52.
Score: 0.004
-
Lung function from infancy to preschool in a cohort of children with cystic fibrosis. Eur Respir J. 2013 Jan; 41(1):60-6.
Score: 0.004
-
Lung function distinguishes preschool children with CF from healthy controls in a multi-center setting. Pediatr Pulmonol. 2012 Jun; 47(6):597-605.
Score: 0.004
-
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med. 2011 Sep; 165(9):847-56.
Score: 0.004
-
Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints. Am J Respir Crit Care Med. 2010 Dec 01; 182(11):1387-97.
Score: 0.004
-
Bronchodilator responsiveness in infants and young children with cystic fibrosis. Am Rev Respir Dis. 1988 Jan; 137(1):119-22.
Score: 0.003
-
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol. 2007 Jul; 42(7):610-23.
Score: 0.003
-
Human metapneumovirus and respiratory syncytial virus infections in older children with cystic fibrosis. Pediatr Pulmonol. 2007 Jan; 42(1):66-74.
Score: 0.003
-
Maximal expiratory flow at FRC (V'maxFRC): Methods of selection and differences in reported values. Pediatr Pulmonol. 2004 Apr; 37(4):318-23.
Score: 0.002
-
Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine. 2003 Jun 02; 21(19-20):2448-60.
Score: 0.002
-
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003 Mar 15; 167(6):841-9.
Score: 0.002
-
Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001 Nov; 32(5):356-66.
Score: 0.002
-
Respiratory diseases in the first year of life in children born to HIV-1-infected women. Pediatr Pulmonol. 2001 Apr; 31(4):267-76.
Score: 0.002
-
Forced expiratory flow in uninfected infants and children born to HIV-infected mothers. Am J Respir Crit Care Med. 2001 Mar; 163(4):865-73.
Score: 0.002
-
Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol. 1999 Nov; 28(5):321-8.
Score: 0.002
-
A lamb model for human respiratory syncytial virus infection. Pediatr Pulmonol. 1993 Mar; 15(3):151-6.
Score: 0.001
-
Total respiratory system compliance in asymptomatic infants with cystic fibrosis. Am Rev Respir Dis. 1987 May; 135(5):1075-9.
Score: 0.001